EGFR and non-small cell lung carcinoma: Data from real-world practice demonstrate a substantial loss of patients in the transition from one line of therapy to the other.36 The recently reported FLAURA trial comparing osimertinib with erlotinib in EGFR-mutant NSCLC indicated that 22% of patients with PD did not receive any second-line treatment and 46–49% had no third-line therapy.37 Thus, patients included into an EAP represent a clearly positively selected population and immortal-time bias should be taken into consideration with regard to OS.